• Depot
  • Watchlist
  • Glocke
  • Handeln

    • BioLine RX News

    0,6101 $ +6,05% +0,0348 $
    In : 0,5706 € | 26.04.24 21:59:54 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PNW3
    ISIN: US09071M2052
    US-Symbol: BLRX
    Typ: Aktie

    BioLine RX News

    17.04.24 - PR Newswire
    BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
    BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ...
    10.04.24 - PR Newswire
    BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
    BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-​Dilutive Debt Financing Agreement PR Newswire
    01.04.24 - PR Newswire
    BioLineRx Announces $6 Million Registered Direct Offering
    BioLineRx Announces $6 Million Registered Direct Offering PR Newswire
    26.03.24 - PR Newswire
    BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
    BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire
    20.03.24 - PR Newswire
    BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
    BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 PR Newswire
    04.03.24 - PR Newswire
    BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
    BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale ...
    28.02.24 - PR Newswire
    BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
    BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-​Line Pancreatic Cancer (PDAC) PR Newswire
    16.02.24 - PR Newswire
    BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
    BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple ...
    21.12.23 - PR Newswire
    BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
    BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell ...
    20.11.23 - PR Newswire
    BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
    BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire
    13.11.23 - PR Newswire
    BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
    BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 PR Newswire
    31.10.23 - PR Newswire
    BioLineRx schließt exklusive Lizenzvereinbarung für Motixafortide in Asien, beraten von M.S.Q. Ventures
    BioLineRx schließt exklusive Lizenzvereinbarung für Motixafortide in Asien, beraten von M.S.Q. Ventures PR Newswire
    31.10.23 - PR Newswire
    BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
    BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures PR Newswire
    12.10.23 - PR Newswire
    BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
    BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment PR Newswire
    03.10.23 - PR Newswire
    Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals?
    Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals? PR Newswire
    02.10.23 - PR Newswire
    Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals?
    Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals? PR Newswire
    29.09.23 - PR Newswire
    Thinking about buying stock in Femasys, Community Health Systems, Opendoor Technologies, Capstone Green Energy, or BioLine RX Ltd?
    Thinking about buying stock in Femasys, Community Health Systems, Opendoor Technologies, Capstone Green Energy, or BioLine RX Ltd? PR Newswire
    28.09.23 - PR Newswire
    BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
    BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-​Line Pancreatic Cancer (PDAC) PR Newswire
    25.09.23 - PR Newswire
    Thinking about buying stock in Mullen Automotive, BioLine RX, Research Solutions, Euroseas, or Virco Mfg?
    Thinking about buying stock in Mullen Automotive, BioLine RX, Research Solutions, Euroseas, or Virco Mfg? PR Newswire
    19.09.23 - PR Newswire
    BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
    BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-​Line PDAC at AACR Special ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »